BIO-RAD LABORATORIES -CL B
BIO.BNYSETrading Snapshot
- Day Range
- $295.81 – $304.27
- 52-Week Range
- $236.73 – $355.85
- Volume
- $3.09B
- Avg Volume
- $3.33B
- Shares Outstanding
- 26.8M
- Next Earnings
- Oct 18, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.62B
- Last Q Revenue
- $721M
- P/E Ratio
- 42.3
- P/S Ratio
- 3.6x
- EPS (TTM)
- $8.25
- Dividend Yield
- —
Why Investors Own BIO.B
- ✓High-growth profile — revenue up +49.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 45% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BIO-RAD LABORATORIES -CL B
A company profile for BIO-RAD LABORATORIES -CL B isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Bio-Rad Laboratories, Inc. Q2 2026 Earnings Call Summary
Moby summary of Bio-Rad Laboratories, Inc.'s Q2 2026 earnings call
Bio-Rad Laboratories Inc (BIO) (Q2 2026) Earnings Call Highlights: Digital PCR Surges 20%+ as ...
Bio-Rad Laboratories Inc (BIO) navigates mixed Q2 with strong Digital PCR growth and Clinical Diagnostics recovery, offset by Life Science softness and China headwinds.
Bio-Rad Laboratories Q2 Earnings Call Highlights
Bio-Rad Laboratories (NYSE:BIO) reported second-quarter revenue of approximately $651 million, essentially flat from $652 million a year earlier on a reported basis and down 1.9% on a currency-neutral basis, as continued softness in academic research markets weighed on its Life Science segment. Pre
Bio-Rad Laboratories (BIO) Beats Q2 Earnings Estimates
Bio-Rad (BIO) delivered earnings and revenue surprises of +11.97% and -0.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call August 4, 2026 5:00 PM EDTCompany ParticipantsRuben Argueta - Vice President of Investor...
Bio-Rad Reports Second-Quarter 2026 Financial Results
HERCULES, Calif., August 04, 2026--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026.